3d
Investor's Business Daily on MSNProtagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks OutProtagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its target price boosted by equities researchers at BMO Capital ...
2d
GlobalData on MSNJ&J and Protagonist’s icotrokinra scores in Phase IIb UC studyGlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
These isekai series explore themes of betrayal, offering viewers gripping stories of protagonists overcoming adversity in ...
The protagonist of the new franchise of Naughty Dog will have an element of difference with respect to other games of the ...
Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.
Grand Theft Auto VI is more than just another sequel in Rockstar’s legendary franchise—it’s a moment of change in the gaming ...
As the Editor of Push Square, Sammy has over 15 years of experience analysing the world of PlayStation, from PS3 through PS5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results